LED Phototherapy kills MRSA @ 405nm

Congratulations to Chukuka et al for taking the inititive to do this work. The outcomes of this high “dose” / short wavelenght invitro study come as no surprise as this effect has been forecast for some time. For decades that UV light has bactericidal effects but that it can also have carcinogenic effects. 405nm is blue light (just outside the range) so should should be a safer option.

Visible 405 nm SLD light photo-destroys methicillin-resistant Staphylococcus aureus (MRSA) in vitro
Enwemeka et al New York Institute of Technology

Background
Infections with MRSA remain a growing public health concern, prompting the need to explore alternative treatments instead of the on-going effort to develop stronger drug-based therapies. We studied the effect of 405 nm blue light on two strains of MRSA – US-300 strain of CA-MRSA and the IS853 strain of HA-MRSA – in vitro.

Methods
We cultured and plated each strain, following which bacteria colonies were irradiated with 0, 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 25, 30, 35, 40, 45, 50, 55, or 60 J cm-2 energy densities – just once – using a Solaris® superluminous diode (SLD) device. Specimens were incubated at 35°C for 24 hours. Then, digital images obtained were quantified to obtain colony counts and the aggregate area occupied by bacteria colonies.

Results
Blue light irradiation produced a statistically significant dose-dependent reduction in both the number and the aggregate area of colonies formed by each bacteria strain (P<0.001). Maximum eradication of the US-300 (92.1%) and the IS-853 colonies (93.5%) was achieved within 9.2 and 8.4 minutes of exposure, respectively. The longer the irradiation the more bacteria were eradicated. However, the effect was non-linear as increases of energy densities between 1.0 and 15 J cm-2 resulted in more bacteria death than similar increases between 15 and 60 J cm-2.

Conclusion
At low doses, blue light photo-destroys HA-MRSA and CA-MRSA in vitro; raising the prospect that phototherapy may be an effective clinical tool in the on-going effort to stem MRSA infections. Lasers Surg. Med. 40:734-737, 2008. © 2008 Wiley-Liss, Inc.

http://www3.interscience.wiley.com/journal/121553714/abstract

About James Carroll

Founder and CEO at THOR Photomedicine Ltd. About THOR
This entry was posted in LLLT. Bookmark the permalink.

Leave a Reply

Your email address will not be published.